PCSK9 and metabolic syndrome: This diversity in baseline LDL-C levels of the patient cohorts ranges from ≥70 mg/dL to >200 mg/dL and points to the fact that the benefits of PCSK9 inhibitors are observed in different severities of dyslipidemia.